Literature DB >> 19344374

Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher-order oligomers in living cells.

Nuria Cabello1, Jorge Gandía, Daniela C G Bertarelli, Masahiko Watanabe, Carme Lluís, Rafael Franco, Sergi Ferré, Rafael Luján, Francisco Ciruela.   

Abstract

G protein-coupled receptors are known to form homo- and heteromers at the plasma membrane, but the stoichiometry of these receptor oligomers are relatively unknown. Here, by using bimolecular fluorescence complementation, we visualized for the first time the occurrence of heterodimers of metabotropic glutamate mGlu(5) receptors (mGlu(5)R) and dopamine D(2) receptors (D(2)R) in living cells. Furthermore, the combination of bimolecular fluorescence complementation and bioluminescence resonance energy transfer techniques, as well as the sequential resonance energy transfer technique, allowed us to detect the occurrence receptor oligomers containing more than two protomers, mGlu(5)R, D(2)R and adenosine A(2A) receptor (A(2A)R). Interestingly, by using high-resolution immunoelectron microscopy we could confirm that the three receptors co-distribute within the extrasynaptic plasma membrane of the same dendritic spines of asymmetrical, putative glutamatergic, striatal synapses. Also, co-immunoprecipitation experiments in native tissue demonstrated the existence of an association of mGlu(5)R, D(2)R and A(2A)R in rat striatum homogenates. Overall, these results provide new insights into the molecular composition of G protein-coupled receptor oligomers in general and the mGlu(5)R/D(2)R/A(2A)R oligomer in particular, a receptor oligomer that might constitute an important target for the treatment of some neuropsychiatric disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19344374      PMCID: PMC3925975          DOI: 10.1111/j.1471-4159.2009.06078.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  58 in total

Review 1.  Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease.

Authors:  K Fuxe; L F Agnati; K Jacobsen; J Hillion; M Canals; M Torvinen; B Tinner-Staines; W Staines; D Rosin; A Terasmaa; P Popoli; G Leo; V Vergoni; C Lluis; F Ciruela; R Franco; S Ferré
Journal:  Neurology       Date:  2003-12-09       Impact factor: 9.910

Review 2.  Adenosine A2A-dopamine D2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders.

Authors:  Sergi Ferré; Francisco Ciruela; Meritxell Canals; Daniel Marcellino; Javier Burgueno; Vicent Casadó; Joëlle Hillion; Maria Torvinen; Francesca Fanelli; Piero de Benedetti Pd; Steven R Goldberg; Michel Bouvier; Kjell Fuxe; Luigi F Agnati; Carme Lluis; Rafael Franco; Amina Woods
Journal:  Parkinsonism Relat Disord       Date:  2004-07       Impact factor: 4.891

3.  Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study.

Authors:  S N Schiffmann; O Jacobs; J J Vanderhaeghen
Journal:  J Neurochem       Date:  1991-09       Impact factor: 5.372

Review 4.  Anatomy of the dopaminergic neuron systems in the rat brain.

Authors:  O Lindvall; A Björklund
Journal:  Adv Biochem Psychopharmacol       Date:  1978

5.  Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes.

Authors:  S Ferre; G von Euler; B Johansson; B B Fredholm; K Fuxe
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

6.  Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies.

Authors:  A I Levey; S M Hersch; D B Rye; R K Sunahara; H B Niznik; C A Kitt; D L Price; R Maggio; M R Brann; B J Ciliax
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

7.  Combining mass spectrometry and pull-down techniques for the study of receptor heteromerization. Direct epitope-epitope electrostatic interactions between adenosine A2A and dopamine D2 receptors.

Authors:  Francisco Ciruela; Javier Burgueño; Vicent Casadó; Meritxell Canals; Daniel Marcellino; Steven R Goldberg; Michael Bader; Kjell Fuxe; Luigi F Agnati; Carmen Lluis; Rafael Franco; Sergi Ferré; Amina S Woods
Journal:  Anal Chem       Date:  2004-09-15       Impact factor: 6.986

8.  Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation.

Authors:  M Jordan; A Schallhorn; F M Wurm
Journal:  Nucleic Acids Res       Date:  1996-02-15       Impact factor: 16.971

9.  Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats.

Authors:  Roberto Coccurello; Nathalie Breysse; Marianne Amalric
Journal:  Neuropsychopharmacology       Date:  2004-08       Impact factor: 7.853

10.  Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer.

Authors:  Meritxell Canals; Daniel Marcellino; Francesca Fanelli; Francisco Ciruela; Piero de Benedetti; Steven R Goldberg; Kim Neve; Kjell Fuxe; Luigi F Agnati; Amina S Woods; Sergi Ferré; Carme Lluis; Michel Bouvier; Rafael Franco
Journal:  J Biol Chem       Date:  2003-08-21       Impact factor: 5.157

View more
  92 in total

1.  Antipsychotic-Like Efficacy of Dopamine D2 Receptor-Biased Ligands is Dependent on Adenosine A2A Receptor Expression.

Authors:  Kristoffer Sahlholm; Maricel Gómez-Soler; Marta Valle-León; Marc López-Cano; Jaume J Taura; Francisco Ciruela; Víctor Fernández-Dueñas
Journal:  Mol Neurobiol       Date:  2017-08-05       Impact factor: 5.590

Review 2.  On the expanding terminology in the GPCR field: the meaning of receptor mosaics and receptor heteromers.

Authors:  Luigi F Agnati; Diego Guidolin; Jean Pierre Vilardaga; Francisco Ciruela; Kjell Fuxe
Journal:  J Recept Signal Transduct Res       Date:  2010-10       Impact factor: 2.092

Review 3.  Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders.

Authors:  K Fuxe; D Marcellino; D O Borroto-Escuela; M Guescini; V Fernández-Dueñas; S Tanganelli; A Rivera; F Ciruela; L F Agnati
Journal:  CNS Neurosci Ther       Date:  2010-03-16       Impact factor: 5.243

Review 4.  Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes.

Authors:  Nicola J Smith; Graeme Milligan
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

5.  G-protein-coupled receptor heteromer dynamics.

Authors:  Jean-Pierre Vilardaga; Luigi F Agnati; Kjell Fuxe; Francisco Ciruela
Journal:  J Cell Sci       Date:  2010-12-15       Impact factor: 5.285

Review 6.  Metabotropic glutamate receptor subtype 5: molecular pharmacology, allosteric modulation and stimulus bias.

Authors:  K Sengmany; K J Gregory
Journal:  Br J Pharmacol       Date:  2015-11-11       Impact factor: 8.739

Review 7.  Heteromeric dopamine receptor signaling complexes: emerging neurobiology and disease relevance.

Authors:  Melissa L Perreault; Ahmed Hasbi; Brian F O'Dowd; Susan R George
Journal:  Neuropsychopharmacology       Date:  2013-06-18       Impact factor: 7.853

Review 8.  Moonlighting proteins and protein-protein interactions as neurotherapeutic targets in the G protein-coupled receptor field.

Authors:  Kjell Fuxe; Dasiel O Borroto-Escuela; Wilber Romero-Fernandez; Miklós Palkovits; Alexander O Tarakanov; Francisco Ciruela; Luigi F Agnati
Journal:  Neuropsychopharmacology       Date:  2013-09-06       Impact factor: 7.853

9.  Functional histamine H3 and adenosine A2A receptor heteromers in recombinant cells and rat striatum.

Authors:  Ricardo Márquez-Gómez; Meridith T Robins; Citlaly Gutiérrez-Rodelo; Juan-Manuel Arias; Jesús-Alberto Olivares-Reyes; Richard M van Rijn; José-Antonio Arias-Montaño
Journal:  Pharmacol Res       Date:  2017-12-05       Impact factor: 7.658

10.  Oligomerization of G-protein-coupled receptors: a reality.

Authors:  Sergi Ferré; Rafael Franco
Journal:  Curr Opin Pharmacol       Date:  2009-12-16       Impact factor: 5.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.